These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16046205)

  • 1. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.
    Epstein S; Zaidi M
    Bone; 2005 Oct; 37(4):433-40. PubMed ID: 16046205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
    Moro-Alvarez MJ; Díaz-Curiel M
    Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.
    Dempster DW; Bolognese MA
    J Clin Densitom; 2006; 9(1):58-65. PubMed ID: 16731432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
    Bauss F; Russell RG
    Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Int J Clin Pract; 2003 Jun; 57(5):417-22. PubMed ID: 12846348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate.
    Simonelli C; Burke MS
    Curr Med Res Opin; 2006 Jun; 22(6):1101-8. PubMed ID: 16846543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ibandronate on bone quality: preclinical studies.
    Bauss F; Dempster DW
    Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.